G R Blumenschein1, E F Smit2, D Planchard3, D-W Kim4, J Cadranel5, T De Pas6, F Dunphy7, K Udud8, M-J Ahn9, N H Hanna10, J-H Kim11, J Mazieres12, S-W Kim13, P Baas14, E Rappold15, S Redhu15, A Puski16, F S Wu15, P A Jänne17. 1. MD Anderson Cancer Center, The University of Texas, Houston, USA. Electronic address: gblumens@mdanderson.org. 2. Department of Pulmonary Diseases, Vrije Universiteit VU Medical Centre, Amsterdam, The Netherlands. 3. Medical Oncology Department, Gustave Roussy (GR), Villejuif, France. 4. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 5. Department of Respiratory Medicine, Hôpital Tenon, Assistance Publique - Hôpitaux de Paris, Paris, France. 6. European Institute of Oncology, Milan, Italy. 7. Duke University Medical Center, Durham, USA. 8. Korányi National Institute of Tuberculosis and Pulmonology, Budapest, Hungary. 9. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 10. IU Melvin and Bren Simon Cancer Center, Indianapolis, USA. 11. Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea. 12. Hopital Larrey CHU Toulouse, Toulouse, France. 13. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 14. Netherlands Cancer Institute, Amsterdam, The Netherlands. 15. GlaxoSmithKline, Collegeville, USA. 16. GlaxoSmithKline Kft., Budapest, Hungary. 17. Lowe Center for Thoracic Oncology, Belfer Institute for Applied Cancer Science Dana-Farber Cancer Institute, Boston, USA.
Abstract
BACKGROUND: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. CLINICALTRIALSGOV REGISTRATION NUMBER: NCT01362296.
BACKGROUND: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. every 3 weeks). Crossover to the other arm after disease progression was allowed. Primary end point was progression-free survival (PFS). The study was prematurely terminated after the interim analysis of 92 PFS events, which showed the comparison of trametinib versus docetaxel for PFS crossed the futility boundary. RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (hazard ratio [HR] 1.14; 95% CI 0.75-1.75; P = 0.5197). Median overall survival, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; 95% CI 0.52-1.83; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). The most frequent adverse events (AEs) in ≥20% of trametinib patients were rash, diarrhea, nausea, vomiting, and fatigue. The most frequent grade 3 treatment-related AEs in the trametinib arm were hypertension, rash, diarrhea, and asthenia. CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. CLINICALTRIALSGOV REGISTRATION NUMBER: NCT01362296.
Authors: Melissa L Johnson; Camelia S Sima; Jamie Chaft; Paul K Paik; William Pao; Mark G Kris; Marc Ladanyi; Gregory J Riely Journal: Cancer Date: 2012-07-18 Impact factor: 6.860
Authors: Jeffrey R Infante; Leslie A Fecher; Gerald S Falchook; Sujatha Nallapareddy; Michael S Gordon; Carlos Becerra; Douglas J DeMarini; Donna S Cox; Yanmei Xu; Shannon R Morris; Vijay G R Peddareddigari; Ngocdiep T Le; Lowell Hart; Johanna C Bendell; Gail Eckhardt; Razelle Kurzrock; Keith Flaherty; Howard A Burris; Wells A Messersmith Journal: Lancet Oncol Date: 2012-07-16 Impact factor: 41.316
Authors: Paul K Paik; Melissa L Johnson; Sandra P D'Angelo; Camelia S Sima; Daphne Ang; Snjezana Dogan; Vincent A Miller; Marc Ladanyi; Mark G Kris; Gregory J Riely Journal: Cancer Date: 2012-05-17 Impact factor: 6.860
Authors: Ryan B Corcoran; Katherine A Cheng; Aaron N Hata; Anthony C Faber; Hiromichi Ebi; Erin M Coffee; Patricia Greninger; Ronald D Brown; Jason T Godfrey; Travis J Cohoon; Youngchul Song; Eugene Lifshits; Kenneth E Hung; Toshi Shioda; Dora Dias-Santagata; Anurag Singh; Jeffrey Settleman; Cyril H Benes; Mari Mino-Kenudson; Kwok-Kin Wong; Jeffrey A Engelman Journal: Cancer Cell Date: 2012-12-13 Impact factor: 31.743
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò Journal: Lancet Oncol Date: 2012-11-28 Impact factor: 41.316
Authors: David M Jackman; Vincent A Miller; Leigh-Anne Cioffredi; Beow Y Yeap; Pasi A Jänne; Gregory J Riely; Marielle Gallegos Ruiz; Giuseppe Giaccone; Lecia V Sequist; Bruce E Johnson Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Mengyu Xie; Hong Zheng; Ranjna Madan-Lala; Wenjie Dai; Nicholas T Gimbrone; Zhihua Chen; Fumi Kinose; Sarah A Blackstone; Keiran S M Smalley; W Douglas Cress; Eric B Haura; Uwe Rix; Amer A Beg Journal: Cancer Res Date: 2019-07-30 Impact factor: 12.701
Authors: Chih-Shia Lee; Liam C Lee; Tina L Yuan; Sirisha Chakka; Christof Fellmann; Scott W Lowe; Natasha J Caplen; Frank McCormick; Ji Luo Journal: Proc Natl Acad Sci U S A Date: 2019-02-01 Impact factor: 11.205
Authors: Laura Esteban-Burgos; Haiyun Wang; Patricia Nieto; Jie Zheng; Carmen Blanco-Aparicio; Carmen Varela; Gonzalo Gómez-López; Fernando Fernández-García; Manuel Sanclemente; Carmen Guerra; Matthias Drosten; Javier Galán; Eduardo Caleiras; Jorge Martínez-Torrecuadrada; Lluis Fajas; Sheng-Bin Peng; David Santamaría; Monica Musteanu; Mariano Barbacid Journal: Proc Natl Acad Sci U S A Date: 2020-09-10 Impact factor: 11.205